PDF(Pubmed)
Abstract：
The incidence of cerebellar Glioblastoma Multiforme (cGBM) is rare. Database like TCGA have not distinguish cGBM from GBM, our knowledge on cGBM gene expression characteristics is limited. The expression status of Oligodendrocyte Lineage Transcription factor 2 (OLIG2) and its clinical significance in cGBM is still unclear.
The clinical data and tissue specimens of 73 cGBM patients were retrospectively studied. The association between OLIG2 expression level and the demographic characteristics of cGBM patients was identified by the Chi-Square test. The survival curves were drawn by Kaplan-Meier analysis. The independent prognostic factors was calculated according to Cox regression analysis.
The OLIG2 high expression was observed in about 57.5% (42/73) of the cGBM patients. Patients with high OLIG2 expression levels had a higher alive ratio at the end of follow-up (alive ratio: 70.6% vs. 29.4%, p = 0.04). The median survival time was 21 months and 13 months for high and low expression of OLIG2 (p < 0 .05). Univariate analysis and Multivariate analysis indicated that EOR (HR = 3.89, 95% CI 1.23‒12.26, p = 0.02), low OLIG2 expression (HR = 5.26, 95% CI 1.13‒24.59, p = 0.04), and without adjuvant therapy (HR = 4.95, 95% CI 1.22‒20.00, p = 0.03) were independent risk factors for the OS of cGBM patients.
High expression level of OLIG2 could be used as an independent favorable prognosis indicator in cGBM patients and be recognized as a characteristic biomarker of cGBM.
The clinical data and tissue specimens of 73 cGBM patients were retrospectively studied. The association between OLIG2 expression level and the demographic characteristics of cGBM patients was identified by the Chi-Square test. The survival curves were drawn by Kaplan-Meier analysis. The independent prognostic factors was calculated according to Cox regression analysis.
The OLIG2 high expression was observed in about 57.5% (42/73) of the cGBM patients. Patients with high OLIG2 expression levels had a higher alive ratio at the end of follow-up (alive ratio: 70.6% vs. 29.4%, p = 0.04). The median survival time was 21 months and 13 months for high and low expression of OLIG2 (p < 0 .05). Univariate analysis and Multivariate analysis indicated that EOR (HR = 3.89, 95% CI 1.23‒12.26, p = 0.02), low OLIG2 expression (HR = 5.26, 95% CI 1.13‒24.59, p = 0.04), and without adjuvant therapy (HR = 4.95, 95% CI 1.22‒20.00, p = 0.03) were independent risk factors for the OS of cGBM patients.
High expression level of OLIG2 could be used as an independent favorable prognosis indicator in cGBM patients and be recognized as a characteristic biomarker of cGBM.
摘要：
小脑多形性胶质母细胞瘤（cGBM）的发生率很少。像TCGA这样的数据库没有区分cGBM和GBM，我们对cGBM基因表达特征的认识有限。少突胶质细胞谱系转录因子2（OLIG2）在cGBM中的表达状况及其临床意义尚不清楚。
对73例cGBM患者的临床资料和组织标本进行回顾性分析。通过卡方检验确定OLIG2表达水平与cGBM患者的人口统计学特征之间的关联。通过Kaplan-Meier分析绘制存活曲线。根据Cox回归分析计算独立预后因素。
在约57.5%(42/73)的cGBM患者中观察到OLIG2高表达。具有高OLIG2表达水平的患者在随访结束时具有更高的存活率(存活率：70.6%vs.29.4%,p=0.04)。OLIG2高表达和低表达的中位生存时间分别为21个月和13个月（p＜0．05）。单因素分析和多因素分析显示EOR(HR=3.89,95%CI1.23~12.26,p=0.02),OLIG2低表达(HR=5.26，95%CI1.13~24.59，p=0.04)，无辅助治疗(HR=4.95,95%CI1.22~20.00,p=0.03)是cGBM患者OS的独立危险因素。
OLIG2的高表达水平可作为cGBM患者独立的良好预后指标，被认为是cGBM的特征性生物标志物。
对73例cGBM患者的临床资料和组织标本进行回顾性分析。通过卡方检验确定OLIG2表达水平与cGBM患者的人口统计学特征之间的关联。通过Kaplan-Meier分析绘制存活曲线。根据Cox回归分析计算独立预后因素。
在约57.5%(42/73)的cGBM患者中观察到OLIG2高表达。具有高OLIG2表达水平的患者在随访结束时具有更高的存活率(存活率：70.6%vs.29.4%,p=0.04)。OLIG2高表达和低表达的中位生存时间分别为21个月和13个月（p＜0．05）。单因素分析和多因素分析显示EOR(HR=3.89,95%CI1.23~12.26,p=0.02),OLIG2低表达(HR=5.26，95%CI1.13~24.59，p=0.04)，无辅助治疗(HR=4.95,95%CI1.22~20.00,p=0.03)是cGBM患者OS的独立危险因素。
OLIG2的高表达水平可作为cGBM患者独立的良好预后指标，被认为是cGBM的特征性生物标志物。
